Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More
Unum Therapeutics acquires kinase inhibitors developer Kiq
Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development of precision kinase inhibitors, in an all-stock ... Read More
TScan, Novartis to develop T cell receptor therapies for solid tumors
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor therapies for the treatment of solid tumors ... Read More
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the ... Read More
PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors
PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in ... Read More
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per ... Read More